ORIGINAL ARTICLEEffects of Prescription Omega-3-Acid Ethyl Esters on Non—High-Density Lipoprotein Cholesterol When Coadministered With Escalating Doses of Atorvastatin
Section snippets
PATIENTS AND METHODS
Men and women were eligible to participate in the study if they were between the ages of 18 and 79 years, medically stable, and, in the judgment of the investigators, otherwise acceptable for entry on the basis of the findings of medical history, physical examination, electrocardiography, and routine laboratory tests. Lipid entry criteria required a non—HDL-C level greater than 160 mg/dL and a triglyceride level between 250 and 599 mg/dL at the end of a diet lead-in period. Women of
RESULTS
A total of 585 patients were screened for eligibility, with 245 patients (41.9%) being randomized (123 to P-OM3 plus atorvastatin and 122 to placebo plus atorvastatin) and 219 (89.4%) completing 16 weeks of study treatment. Disposition of patients is shown in Figure 1. Baseline characteristics of randomized patients (Table 1) revealed no statistically significant differences between the 2 groups. The mean age of study participants was 56 years, and most randomized patients were men (142/245
DISCUSSION
In this study, coadministration of P-OM3, 4 g/d, with atorvastatin, 10 to 40 mg/d, lowered non—HDL-C levels to a significantly greater extent than the same dose of atorvastatin alone in patients with elevated triglyceride and non—HDL-C levels. The effects of adding P-OM3 to either 10 or 20 mg/d of atorvastatin were comparable to that of doubling the atorvastatin dose in lowering non—HDL-C levels.
Combining P-OM3, 4 g/d, with atorvastatin also reduced median TC, triglyceride, and VLDL-C levels
CONCLUSION
Coadministration of P-OM3 with 10 to 40 mg of atorvastatin significantly reduced non—HDL-C levels compared to the same dose of atorvastatin alone in patients with elevated non—HDL-C and triglyceride levels. In addition, P-OM3 improved other lipid parameters. Generally, P-OM3 added to atorvastatin was well tolerated at all atorvastatin doses. Coadministration of P-OM3 with statin therapy may be a rational treatment approach for improving non—HDL-C levels and other lipid parameters in patients
Acknowledgments
We acknowledge the following individuals for their contributions to the draft development and critical review of the submitted manuscript: Rose Snipes, MD; Amy Meadowcroft, PharmD; Rosemary Schroyer, MS; and Doug Wicks, MPH.
REFERENCES (27)
- et al.
Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation
J Am Coll Cardiol
(2008) - et al.
Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk
J Am Coll Cardiol
(2009) - et al.
Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations
Am J Cardiol
(2005) - et al.
Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study
Clin Ther
(2007) - et al.
Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity
Am J Clin Nutr
(2006) - et al.
Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia [published correction appears in am J Cardiol. 2008;102(10):1425]
Am J Cardiol
(2008) - et al.
Dietary long-chain n-3 PUFAs increase LPL gene expression in adipose tissue of subjects with an atherogenic lipoprotein phenotype
J Lipid Res
(2002) - et al.
Trans geometric isomers of EPA decrease LXRα-induced cellular triacylglycerol via suppression of SREBP-1c and PGC-1β
J Lipid Res
(2006) - et al.
Effect of prescription omega-3 fatty acids coadministered with escalating doses of atorvastatin in patients with hypertriglyceridemia [abstract 5150]
Circulation
(2008) - Bays HE, McKenney J, Doyle RT, Carter RN, Stein E. Prescription omega-3s coadministered with atorvastatin for patients...
Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report
Circulation
Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications
Expert Rev Cardiovasc Ther
Cited by (51)
Indications for Omega-3 Long Chain Polyunsaturated Fatty Acid in the Prevention and Treatment of Cardiovascular Disease
2015, Heart Lung and CirculationCitation Excerpt :Hypertriglyceridaemia represents a situation in which the relationship between LDL-cholesterol and CHD risk is moderately confounded by changes in LDL-composition, and it is possible that the difference between total and HDL-cholesterol, the so-called “non-HDL” cholesterol, may represent a more accurate estimate of CHD risk. Omega-3 LCPUFAs have been shown to favourably reduce non-HDL cholesterol [35]. These data confirm omega-3 LCPUFA as a means for lowering plasma triglyceride levels (Grade A).
Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa for Lowering Very high triglyceridEs (EVOLVE) trial
2014, Journal of Clinical LipidologyOmega-3 polyunsaturated fatty acids in the treatment of hypertriglyceridaemia
2013, International Journal of CardiologyUpdate on marine omega-3 fatty acids: Management of dyslipidemia and current omega-3 treatment options
2013, AtherosclerosisCitation Excerpt :OM3EE has also been studied in patients receiving atorvastatin [42]. Significant reductions were noted for TG, non-HDL-C, and VLDL-C levels, while changes in LDL-C and Apo B levels were not statistically significant [42]. OM3EE was generally well tolerated in clinical trials; adverse events reported by ≥3% of patients that occurred more frequently than in patients receiving placebo were eructation, dyspepsia, and taste perversion [37].
Portions of this manuscript have been presented in abstract and poster presentations.1, 2, 3
Manuscript writing and editing support by Kevin Jarvis, PharmD, from BioCentric, inc, was funded by GlaxoSmithKline. Funding for this study was provided by GlaxoSmithKline, Research Triangle Park, NC (NCT00435045).
Dr Bays and Dr Maki have served as clinical investigators, received research grants, and received consultant, adviser, and speaker fees from numerous pharmaceutical companies, including Reliant and GlaxoSmithKline. Mr Doyle is a former employee of Reliant Pharmaceuticals and has received consultant fees from GlaxoSmithKline. Dr Carter is currently the CEO of WellGen Inc. Dr McKenney serves as a consultant for Abbott Laboratories, Agerion, AstraZeneca, GlaxoSmithKline, Merck & Co, and Daiichi Sankyo. Dr Stein has received consulting fees, honorarium, or research funding for specific clinical trials from GlaxoSmithKline, Reliant Pharmaceuticals, Merck & Co, Schering Plough, Daiichi Sankyo, AstraZeneca, Abbott, ISIS, Genzyme, and Food and Drug Administration.
This article is freely available on publication, because the authors have chosen the immediate access option.